Top Markets
#1 Doge Strategy Doge Strategy +953,314.18%
#2 Noon Noon +12,208.80%
#3 Siren Siren +112.06%
#4 NEW X CEO IS BACK NEW X CEO IS BACK +109.20%
#5 Venom Venom +46.63%
#6 Gigachad Gigachad +28.15%
#7 Ontology Ontology +20.38%
#8 Scor Scor +18.84%
#9 Win Win +17.98%
#10 TRIA TRIA +17.79%
Coin of the day
Doge Strategy Doge Strategy
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Noxopharm Limited Noxopharm Limited

Noxopharm Limited

NOX
Rang in aandelen #17276
Noxopharm Limited, a drug development company, focuses on developing treatment... Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.
Aandeelprijs
$0.0416118
Marktkapitalisatie
$12.78M
Verandering (1 dag)
1.72%
Verandering (1 jaar)
-22.01%
Land
AU
Handel Noxopharm Limited (NOX)

Categorie

Healthcare
Operationele marge voor Noxopharm Limited (NOX)
Operationele marge op March 2026 TTM: -532.32%
Volgens de meest recente financiële rapporten en aandelenkoers van Noxopharm Limited is de huidige operationele marge (TTM) -532.32%. Eind 2024 had het bedrijf een operationele marge van -313.92%.
Geschiedenis van de operationele marge van Noxopharm Limited van 2016 tot 2026
Operationele marge aan het einde van elk jaar
Jaar Operationele Marge Wijzigen
2026 (TTM) -532.32% 55.59%
2025 -342.14% 8.99%
2024 -313.92% 13.69%
2023 -276.12% -1.43%
2022 -280.14% 7.54%
2021 -260.50% 31.83%
2020 -197.61% -52.69%
2019 -417.69% -63.54%
2018 -1,145.69% -55.34%
2017 -2,565.11% 0.00%
2016 0.00% 0.00%
Operationele marge van vergelijkbare bedrijven of concurrenten
Bedrijf Operationele Marge Verschil in operationele marge Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
41.30% -100.08%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
35.45% -100.07%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
24.95% -100.05%
US
UCB SA UCB SA
UCB SA
UCB.BR
25.32% -100.05%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -100.05%
AU
Wat is de Operationele marge van een bedrijf?
De Operationele marge is een belangrijke indicator om de winstgevendheid van een bedrijf te beoordelen. Hogere operationele marges zijn over het algemeen beter omdat ze aangeven dat een bedrijf zijn producten of diensten veel duurder kan verkopen dan de productiekosten. De Operationele marge wordt berekend door de winst van een bedrijf te delen door de omzet.